Half Year Results to 31 March 2021
RNS Number : 5562D
Catenae Innovation PLC
30 June 2021
30 June 2021
Catenae Innovation PLC
("Catenae", the "Company" or the "Group")
Half Year Results to 31 March 2021
Catenae Innovation PLC (AIM: CTEA), the AIM quoted provider of digital media and technology, announces its half-yearly report for the six months ended 31 March 2021.
Financial overview
Loss of £586,798 in the period under review (2020: £379,384) with revenues of £12,308 (2020: £4,5211).
Placing in January 2021 raised gross proceeds of £1.0m, improving Catenae's net asset position to £1,035,493 (2020 net liabilities: £549,2121).
Operational overview
Signed a 50/50 JV agreement with the UK and South African entities of the medical equipment and Covid-19 test kit supply company, Blackhive Africa Medical ("BHA-Medical"), to deliver an integrated COVID-19 'Test, Monitor & Manage Programme'. The JV company was renamed Synovate Global Limited ("Synovate").
Entered into a Memorandum of Understanding ("MoU") with Afrik-ID to commercialise potential opportunities within Botswana and SADC (South Africa Development Community).
Reached commercial agreements with Badminton England, Stone Bailey (for use at Lapland UK), a Fortune 500 American professional services and engineering company, a major UK mobile operator and a chain of 18 pharmacies for its COVID-19 testing platform, feeding results into Public Health England's (PHE) database.
Enhanced the Company's IP through the development of bespoke mobile apps and dynamic dashboards for the visualisation of data sets.
Awarded ISO 27001 accreditation following an audit on behalf of the International Standards Organisation (ISO), and a Cyber Essentials accreditation, a scheme that is operated on behalf of the National Cyber Security Centre (NCSC).
Invited by the UK Government's Department for Digital, Culture, Media and Sport ("DCMS") to participate in the development of the Digital Identity and Trust Attributes Framework Policy.
Appointed Nick Delacamp as Chief Commercial Officer (non-Board role) in December 2020.
Post period end
Acquisition of 51% interest in Hyperneph Software Limited ("Hyperneph") in May 2021 to secure and enhance the Company's ability to deliver innovative software-based solutions.
Guy Meyer, Chief Executive Officer of Catenae, said:
"Notwithstanding Catenae's JV with BHA-Medical and its efforts to offer Onsite ID to organisations to securely record COVID-19 test and vaccine status and then pass this data onto PHE, as well as for users to be able to present their status via its GDPR compliant mobile app, short-notice changes to the UK Government's pandemic strategy meant that commercial traction was impeded, and the Company did not generate material revenues in the period.
"The Board believes that the Company's product set retains significant value and, with support from Nick Delacamp, our recently appointed Chief Commercial Officer, the Company has a healthy pipeline of non-COVID-19 related opportunities that will allow us to leverage our technology for use in other markets.
"Our acquisition of Hyperneph post period end also strengthens and expands the Group's product offering, positioning us in good stead for the remainder of the year as we look to broaden our network and reach a wider audience.
"Catenae's ongoing consultation with DCMS in the development of the Digital Identity and Trust Attributes Framework Policy reflects the Company's standing in the sector. Our investment in software IP development also contributes to the future-proofing of our competitive product set offerings.
"We look forward to keeping the market updated on how these opportunities progress."
For further information please contact:
| Catenae Innovation PLC | +44 (0)191 580 8545 |
| Guy Meyer, Chief Executive Officer | |
| Cairn Financial Advisers LLP (Nominated Adviser) | +44(0)20 7213 0880 |
| Liam Murray / Jo Turner | |
| Brandon Hill Capital Limited, Broker | +44 (0)20 3463 5000 |
| Andy Gutmann | +44 (0)78796 8313 |
| Yellow Jersey PR (PR & IR) | +44 (0)20 3004 9512 |
| Sarah Hollins / Annabel Atkins / Matthew McHale |
| Unaudited six months ended 31 March 2021 £ | Unaudited six months ended 31 March 2020 Restated £ | Audited year ended 30 Sept 2020 £ | |
| Revenue | 12,308 | 4,5211 | 14,948 |
| Cost of sales | - | - | - |
| Gross profit | 12,308 | 4,521 | 14,948 |
| Administrative expenses | (599,116) | (360,615) | (759,108) |
| (586,808) | (356,094) | (744,160) | |
| Loss from operations | (586,808) | (356,094) | (744,160) |
| Net Finance income/(expense) | 10 | (23,290) | (25,026) |
| Loss before taxation | (586,798) | (379,384) | (769,186) |
| Taxation credit | - | - | - |
| Total comprehensive loss for the year | (586,798) | (379,384) | (769,186) |
| Unaudited six months ended 31 March 2021 £ | Unaudited six months ended 31 March 2020 Restated £ | Audited year ended 30 Sept 2020 £ | ||
| Non-current assets | ||||
| Intangible assets | 1 | 1 | 1 | |
| 1 | 1 | 1 | ||
| Current assets | ||||
| Trade and other receivables | 47,475 | 15,161 | 20,604 | |
| Cash and cash equivalents | 1,254,445 | 910 | 714,043 | |
| 1,301,920 | 16,071 | 734,647 | ||
| Current liabilities | ||||
| Trade and other payables | (248,428) | (565,283) | (214,221) | |
| (248,428) | (565,283) | (214,221) | ||
| Non current liabilities | ||||
| Interest-bearing loans | (18,000) | - | (18,000) | |
| Total Liabilities | (266,428) | (565,283) | (232,221) | |
| Net Assets/(Liabilities) | 1,035,493 | (549,212) | 502,427 | |
| Capital and reserves attributable to equity holders of the company | ||||
| Ordinary share capital | 551,773 | 3,373,601 | 442,183 | |
| Deferred share capital | 3,159,130 | - | 3,159,130 | |
| Share premium account | 19,663,223 | 17,439,221 | 18,652,949 | |
| Share reserve | (83,333) | (83,333) | (83,333) | |
| Merger reserve | 11,119,585 | 11,119,585 | 11,119,585 | |
| Capital Redemption Reserve | 2,732,904 | 2,732,904 | 2,732,904 | |
| Retained losses | (36,107,789) | (35,131,190) | (35,520,991) | |
| Total Equity | 1,035,493 | (549,212) | 502,427 |
| Unaudited six months ended 31 March 2021 £ | Unaudited six months ended 31 March 2020 Restated £ | Audited year ended 30 Sept 2020 £ | |
| Loss for the period | (586,798) | (379,384) | (769,186) |
| Adjustments for: | |||
| Net bank and other interest (income) / charges | (10) | 23,290 | 25,026 |
| Issue of share options / warrant charge | - | - | - |
| Services settled by the issue of shares | 48,000 | - | - |
| Net (loss) before changes in working capital | (538,808) | (356,094) | (744,160) |
| (Increase) / decrease in trade and other receivables | (34,766) | 23,158 | (2,344) |
| (Decrease) / increase in trade and other payables | (5,898) | 154,628 | (62,210) |
| Cash from operations | (579,472) | (178,308) | (808,714) |
| Interest received | 10 | 10 | 28 |
| Interest paid | - | (23,300) | (25,054) |
| Net cash flows from operating activities | (579,462) | (201,598) | (833,740) |
| Investing activities | |||
| Investment in joint venture | - | - | - |
| Net cash flows from investing activities | - | - | - |
| Financing Activities | |||
| Issue of ordinary share capital | 1,119,864 | 153,000 | 1,481,855 |
| Repayment of loans | - | - | (96,580) |
| New loans raised | - | 20,000 | 133,000 |
| Net cash flows from financing activities | 1,119,864 | 173,000 | 1,518,275 |
| Net increase / (decrease) in cash | 540,402 | (28,598) | 684,535 |
| Cash and cash equivalents at beginning of period | 714,043 | 29,508 | 29,508 |
| Cash and cash equivalents at end of period | 1,254,445 | 910 | 714,043 |